The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients (SIDIACO)
Covid19, Diabetes Mellitus, Type 2, CKD
About this trial
This is an interventional treatment trial for Covid19
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of type 2 diabetes, according to ADA 2020 criteria
- HbA1c levels at the entrance or in the two previous months <9%
- Diagnosis of Covid-19 (swab for positive SARS-COV2 RNA) with pneumonia, with or without increase in inflammation indexes, with or without respiratory failure
- No indication for tocilizumab therapy (BCRSS, Brescia Covid Respiratory Severity Scale, <3).
- Written and dated informed consent from the patient or his legally valid representative
Exclusion Criteria:
- Pregnancy
- Type 1 diabetes
- Stage IV and V renal failure (stimated glomerular filtration rate <30 ml / min)
- Treatment with Dipeptidyl peptidase-4 inhibitors or GLP-1 Receptor Agonists in the month prior to hospitalization
- Pioglitazone treatment in the month prior to hospitalization
- Treatment in the month preceding or in the course of hospitalization with "biological" drugs for immuno-rheumatological diseases (in particular tocilizumab)
- Presence of other acute or chronic ongoing infections
- Neurological or psychiatric diseases, diagnosis of hemoglobinopathy, diagnosis of liver disease, cancer, cystic fibrosis or malabsorption syndrome
- Dysphagia with need for artificial nutrition
- Positive history of acute and chronic pancreatitis
- Unstable cardiovascular disease or known atherosclerotic disease
- A history of alcohol or drug abuse
- Known human immunodeficiency virus (HIV) or hepatitis
- Presence of serious diseases or conditions that make the patient unsuitable for the study
- Surgery in the previous two weeks
Sites / Locations
- ASST FBF Sacco
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Treatment group
Control group
patients will be treated with sitagliptin add on to nutritional therapy with o without insulin treatment. The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
Patients who will be prescribed nutritional therapy with or without insulin treatment